The formulation containing HPMC K15MCR and Polyox WSR at the Sorry, there is no online preview for this file type. Ranitidine can be found in many pharmaceutical firms such as tablets, injectable solutions and oral Dissolution enhancement of aceclofenac tablet by solid dispersion technique. short biological half life demands continuous intravenous infusion or time spaced injection. We chose tristearin as solid lipid and formulated it in nanoparticulate form by an ultrasonic Sorry, there is no online preview for this file type. Enhanced skin delivery of aceclofenac via hydrogel-based solid lipid nanoparticles. Injectable. Moderate. REACTION TO SEPTRIN PROPHYLAXIS IN A NEWLY STARTED SWEATING WITH CHANGE IN HAEMODYNAMIC STABILITY. 1. 1 Injectable. Mild. 2. ORAL DICLOFENAC 50MG, HAEMOPTYSIS.
|Country:||Central African Republic|
|Published (Last):||15 October 2014|
|PDF File Size:||19.54 Mb|
|ePub File Size:||15.33 Mb|
|Price:||Free* [*Free Regsitration Required]|
Clarity test was performed by visually inspecting the externally clean vial under a good light, baffled against reflection into the eyes, and viewed against black and white background, with the content set in swirling motion. The stable injectable pharmaceutical composition of the present invention as prepared in example 2 was subjected to stability studies before lyophilization and the results are shown in table 3.
It is practically insoluble in water. The present aceclofeac utilizes arginine or its pharmaceutically acceptable salt forms, preferably L-arginine or arginine hydrochloride, more preferably L-arginine for solubilization. Quantitative analysis of formu,ation tablets using lignocaine hydrochloride as hydrotropic agent.
US20090156670A1 – Nonaqueous liquid parenteral aceclofenac formulation – Google Patents
In conclusion, non-inferiority of the analgesic efficacy of aceclofenac compared with diclofenac resinate was demonstrated in patients with localised, uncomplicated acute lumbosacral pain.
Howeveribuprofen is very slightly soluble in water and readily soluble in 5 ethanol. Where a range; of values is provided, k is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention.
The composition ihjection water-insoluble Aceclofenac, a polymeric base and a surfactant.
Rajkumar Gupta – Google+
Accordingly, it is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative. This technique can provide additive or synergistic enhancement effect on solubility of poorly water-soluble drugs.
While the above description contains many specificities, these should not be construed as aceclofenav in re scope of the invention, but rather as an exemplification of the preferred embodiments thereof. Other object of the present invention is to provide a formulation which is convenient to use and stable for much longer time as compared to dry powder aceclofenac injection.
Parenteral administration can also result filettpe more predictable blood serum concentrations of a drug, because losses in the gastrointestinal tract due to metabolism, binding to food and other causes are eliminated.
The Aceclofenac forjulation of any of Items 1 and 5, wherein said nonaqueous solubilizer component is selected from the group consisting of polyethylene glycol, polyethylene glycol and optional ethanol. Acetic and acid group: We have found that adjusting the pH of the solution of arginine and aceclofenac in between about 6. The Aceclofenac filrtype of any one of claims 1 and 5wherein filetypd nonaqueous solubilizer component is selected from the group consisting of propylene glycol, polyethylene glycol and ethanol.
The amount of individual hydrotropic agent required is less, compared to the other blends with higher solubilities. The Aceclofenac formulation of Item 19 wherein flietype Aceclofenac salt is Aceclofenac Sodium, which acecpofenac filled asceptically under inert gas blanket.
Lamitubes offer excellent barrier to oxygen, moisture, aroma loss. A process for preparing a nonaqueous liquid parenteral Aceclofenac formulation for pharmaceutical application, which process comprises the steps of:. Non aqueous injectable pharmaceutical compositions of lipophilic ” water-insoluble drugs like aceclofenac frequently consist of mixtures of water, organic cosolvents and surfactants.
Neoplasias for diletype compositions of the invention are contemplated to be particularly useful are gastrointestinal cancer, Barrett’s esophagus, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, cervical cancer, lung cancer, breast cancer and skin cancer.
The Aceclofenac formulation of Item 19 wherein required amount of said effective dosage is provided in a sealed airtight container which is selected from the group consisting of a vial, an ampoule, a syringe, a packet, a pouch and an auto—injector.
Rheumatoid arthritis RA is a chronic inflammatory disease of the joint space which involves synovial proliferation and cartilage destruction. Preparation method and application of medicament-cyclodextrin inclusion compound self-emulsifying composition. A Country of ref document: Currently more than 50 hospitals have been red listed. Salts of 2- 2,6-dichlorophenyl amine!
USA1 – Nonaqueous liquid parenteral aceclofenac formulation – Google Patents
A method of Item 30 wherein said disorder is COX-2 mediated and wherein said therapeutically effective amount is a daily dosage of about 1 mg per day to about mg per day, preferably of about 10 mg per day to about mg per day, more preferably of about 30 mg per day to about mg per day, still more preferably of about 50 mg per day to about mg per day. Then required volume was made up by water for injection and adjusting the pH of about acecloffenac. The Aceclofenac formulation of Item 20, wherein interior space of said sealed airtight container comprises a fill volume occupied by said Aceclofenac formulation and a filettpe volume occupied by and inert —gas—limited microatmosphere, which microatmosphere comprises essentially of one or more inert gases selected from the group consisting of noble gases and nitrogen such that the ratio of said fill volume to said headspace fi,etype is not less than formilation In addition, when being orally administered in an amount much smaller than the conventional preparation, the oral preparation is therapeutically effective, thus minimizing gastrointestinal disorder.
Arginine is a conditionally nonessential amino acid, meaning most of the time it can be manufactured by the human body, and does not need to be obtained directly through the diet. The fact that, at baseline, both these variables were significantly greater in the aceclofenac than in the diclofenac group suggests that the RA iniection may have been more severe in the aceclofenac group and that the efficacy of this drug may have been somewhat greater, since there was no difference between the groups after 6 months.
The Aceclofenac formulation of any of Items 1 and 5 wherein said nonaqueous solubilizer component is selected from the group filegype of propylene glycol and optional ethanol.